CARB-X is a non-profit public-private partnership with the mission to advance research on antimicrobial resistance globally. The focus lies on innovative research and the development of novel antibacterial agents and therapies designed to counteract the rising burden of antimicrobial resistance. CARB-X currently supports more than 30 projects on early stages of development of antibiotics, other therapeutics, vaccines and diagnostics. In the beginning of 2019 Germany has participated in the CARB-X initiative. With around 40 million euros, the BMBF will continuously support the global partnership for the next 5 years.